Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Bristol Myers Squibb reported a death after an investigational CAR-T treatment in an early multiple-sclerosis study.
TL;DR
- Bristol Myers Squibb reported that a patient died after receiving its investigational CAR-T therapy in an early multiple-sclerosis trial.
- The company said the patient developed septic pneumonia after receiving an immunosuppressant for persistent motor symptoms.
- The available reports do not establish that the therapy caused the death, and the trial’s broader safety assessment remains open.
Bristol Myers Squibb disclosed that a participant in an early study of its investigational CAR-T therapy for multiple sclerosis died. STAT reported the disclosure on October 23, and Bloomberg Law separately covered the event. [1] [2]
According to the company’s account reported by STAT, the patient experienced motor symptoms that did not resolve with standard autoimmune treatments. The patient then received an immunosuppressant and later developed septic pneumonia. [1]
The report identifies the sequence of events but does not establish that the cell therapy caused the infection or death. The company’s disclosure is a safety report from an investigational study, not a regulatory finding about causality. [1] [2]
The case adds to scrutiny of CAR-T approaches being studied for autoimmune disease. The cited coverage does not provide a final investigation, a complete trial-wide adverse-event analysis, or a decision on the program’s status. [1] [2]
Why it matters
CAR-T is being studied beyond cancer, where its immune effects are being tested in chronic conditions. A death during an early trial makes the distinction between an observed safety event and a confirmed treatment-related risk central to subsequent regulatory and clinical assessment.
Editor's note
STAT reports the company’s account; Bloomberg Law independently covers the disclosure. Causality is not established in the cited reports.